论文部分内容阅读
近几十年来,一方面深部真菌感染发生率呈显著上升趋势,另一方面真菌耐药性包括天然耐药和获得性耐药成为侵袭性真菌感染治疗失败的主要原因之一。现有抗真菌药物品种数量有限且联合应用协同作用不明显,寻找新的小分子化合物作为已有抗真菌药物的增效剂来发挥协同作用,可成为治疗侵袭性真菌感染的新策略。本文结合本课题组的研究工作及国内外报道的具有协同抗耐药真菌活性的天然小分子化合物的研究工作进行综述,对它们的来源、结构、药理活性和作用机制进行分析,以寻找其中的共性规律,为抗耐药真菌的创新药物研发提供理论基础。
In recent decades, on the one hand, the incidence of deep fungal infections showed a significant upward trend. On the other hand, fungal drug resistance, including natural resistance and acquired drug resistance, became one of the main reasons for the failure of treatment of invasive fungal infections. The existing antifungal drugs are limited in quantity and synergistic effect is not obvious. Looking for new small molecule compounds as synergists of existing antifungal drugs can be a new strategy for the treatment of invasive fungal infections. In this paper, the research work of our group and the reports of natural small molecule compounds with synergistic antifungal fungal activity reported at home and abroad are summarized, their origin, structure, pharmacological activity and mechanism of action are analyzed in order to find out the Common law for the development of innovative drug-resistant fungi provide the theoretical basis.